Biotech entity

Rumble

Company RUM

pharma is the sole category represented across all 1 tracked stories. Rumble is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Rumble, all published on March 5, 2026.

Last mentioned: Mar 5, 2026

Entity pulse

Recent coverage · Rumble

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Rumble

pharma is the sole category represented across all 1 tracked stories. Rumble is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Rumble, all published on March 5, 2026. Each carries 5 original sources on average.

Stories tracked
1
Sources per story
5

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Rumble. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Rumble 1

Pharma Neutral

Biotech Earnings: Atea and Profound Medical Signal Strategic Shifts in 2026

Atea Pharmaceuticals and Profound Medical headlined a busy earnings day for the biotech sector, revealing critical updates on antiviral pipelines and therapeutic device adoption. As companies report full-year 2025 results, the focus remains on cash preservation and the transition from R&D to commercial execution.

5 sources

Rumble is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.